Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated Diabetes

This project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications.

Subsidie
€ 3.885.462
2023

Projectdetails

Introduction

It will be a radically new approach for long-term continuous monitoring of insulin-treated persons with diabetes (ITD) moving from a glucose-only to a multi-metabolite monitoring - glucose, lactate, and 3 OH-butyrate paradigm.

Multi-Metabolite Monitoring

Multi-metabolite monitoring will also lead to a diabetes therapy breakthrough by algorithmically driving a continuous physiologic insulin delivery by a maintenance-free implanted MEMS pump using the peritoneal route. This will enable an optimal therapy for subjects with ITD.

Vision

Our vision is a fully implantable artificial organ to replace insulin secretion loss by targeting metabolic health instead of mere glucose control and mimicking physiological insulin action.

Benefits

While offering a really burden-free life for insulin-treated children and adults, it is expected to allow:

  • A dramatic reduction of metabolic variations
  • Minimization of acute and long-term complications
  • An abating of the still high mortality of T1D patients

Unobtrusive Living

Unobtrusive living with diabetes will be reached by the calibration-free, implantable, long-term multi-metabolite monitoring solution connected wirelessly to a novel highly miniaturized silicon MEMS micropump.

Specifications

  • Stroke volume down to 50 nl
  • Ability to operate a newly developed U1000 insulin
  • Reservoir refill cycles of 180 days up to 365 days

Both devices hold a durable battery operating life of more than 8 years without recharge and are suitable for children.

Control Algorithms

Newly designed control algorithms based upon multiple signal inputs will drive automated insulin delivery without the need for obtrusive meal and physical exercise announcements.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 3.885.462
Totale projectbegroting€ 3.885.462

Tijdlijn

Startdatum1-10-2023
Einddatum30-9-2027
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EVpenvoerder
  • UNIVERSITA DEGLI STUDI DI PADOVA
  • UNIVERSITA DEGLI STUDI DI PAVIA
  • CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER
  • INDIGO DIABETES
  • FIDAM GMBH
  • EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH

Land(en)

GermanyItalyFranceBelgium

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"

The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation.

€ 2.996.550
EIC Pathfinder

Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.

The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images.

€ 2.744.300
EIC Pathfinder

Dynamic Spatio-Temporal Modulation of Light by Phononic Architectures

Dynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements.

€ 2.552.277
EIC Pathfinder

Emerging technologies for crystal-based gamma-ray light sources

TECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology.

€ 2.643.187

Vergelijkbare projecten uit andere regelingen

EIC Transition

MICRO-MECHANICAL PUMP FOR NEXT GENERATION INSULIN DELIVERY SYSTEMS

PRISMA aims to validate a novel, ultra-compact micropump for wearable insulin delivery, enhancing accuracy and efficiency to revolutionize diabetes treatment and enable multi-drug systems.

€ 2.499.838
ERC POC

Sensor islet organoids (SILORGS) for in vivo identification of anti-diabetic drugs

Develop a non-invasive in vivo imaging platform using sensor islet organoids in mice to assess β-cell function and survival for validating new diabetes treatments.

€ 150.000
EIC Accelerator

Minimally invasive reliAble Glucose monitoring in Intensive Care

GlucoSet aims to develop a novel continuous glucose monitor for ICU patients to improve glucose control, enhance patient outcomes, and achieve CE-mark approval within 25 months.

€ 2.500.000
EIC Accelerator

The world’s first needle-free continuous glucose monitor to prevent and manage diabetes at scale

Developing a non-invasive glucose monitoring device to improve diabetes management and prevent onset for over 2 billion people through EIC blended finance support.

€ 2.500.000